Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 3/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27842415 | 0.86 | EPHX1 (0.49) | SMN1; SMN2EPHX1LMNAHPGDKMT2A | |
| SCHEMBL4626998 | 0.84 | TDP1 (0.40) | SMN1; SMN2L3MBTL1LMNAKMT2AALDH1A1 | |
| SCHEMBL2265099 | 0.84 | SMN1; SMN2 (0.46) | SMN1; SMN2EPHX1LMNAHPGDKMT2A | |
| SCHEMBL1734362 | 0.83 | EPHX1 (0.46) | SMN1; SMN2EPHX1LMNAHPGDKMT2A | |
| SCHEMBL8395728 | 0.82 | SMN1; SMN2 (0.45) | SMN1; SMN2EPHX1LMNAHPGDKMT2A | |
| SCHEMBL1439009 | 0.82 | L3MBTL1 (0.41) | SMN1; SMN2EPHX1L3MBTL1LMNAHPGD | |
| SCHEMBL8394699 | 0.82 | SMN1; SMN2 (0.45) | SMN1; SMN2EPHX1LMNAHPGDKMT2A | |
| SCHEMBL11096063 | 0.82 | L3MBTL1 (0.41) | SMN1; SMN2EPHX1L3MBTL1LMNAHPGD | |
| SCHEMBL8893833 | 0.82 | SMN1; SMN2 (0.45) | SMN1; SMN2EPHX1LMNAHPGDKMT2A | |
| SCHEMBL16470982 | 0.82 | SMN1; SMN2 (0.49) | SMN1; SMN2EPHX1LMNAKMT2ANAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114585637-A | MASP inhibiting compounds and uses thereof | 拜耳公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20060183753-A1 | Use of substituted 2,5-diamidoindoles for the treatment of urological diseases | BAYER HEALTHCARE AG (DE) | 2006-08-17 | — | — | US | disclosed |
| US-7045544-B2 | Substituted 2,5-diamidoindoles as ECE inhibitors for the treatment of cardiovascular diseases | BAYER HEALTHCARE AG (DE) | 2006-05-16 | — | — | US | disclosed |
| US-20050038101-A1 | Substituted 2 5-diamidoindoles as ece inhibitors for the treatment of cardiovascular diseases | BAYER HEALTHCARE AG (DE) | 2005-02-17 | — | — | US | disclosed |
| US-4937251-A | TREATING ASTHMA AND BRONCHITIS; ADRENERGIC STIMULANTS | GLAXO GROUP LIMITED (GB) | 1990-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183753-A1 | Use of substituted 2,5-diamidoindoles for the treatment of urological diseases | DCK, UROD, QDPR | SMN1; SMN2 3855/4885EPHX1 3702/4885L3MBTL1 3676/4885 |
| US-20050038101-A1 | Substituted 2 5-diamidoindoles as ece inhibitors for the treatment of cardiovascular diseases | ECE1, ECE2, EDNRA | SMN1; SMN2 3478/4885EPHX1 192/4885L3MBTL1 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.